Zacks Research Predicts Masimo’s Q1 Earnings (NASDAQ:MASI)

Masimo Co. (NASDAQ:MASI) – Zacks Research issued their Q1 2025 EPS estimates for Masimo in a note issued to investors on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay anticipates that the medical equipment provider will post earnings of $1.25 per share for the quarter. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo’s Q2 2025 earnings at $1.28 EPS, Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.47 EPS, FY2025 earnings at $5.32 EPS, Q1 2026 earnings at $1.41 EPS, Q2 2026 earnings at $1.45 EPS, Q3 2026 earnings at $1.44 EPS, Q4 2026 earnings at $1.60 EPS and FY2026 earnings at $5.90 EPS.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million.

A number of other equities research analysts have also weighed in on the stock. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Wells Fargo & Company boosted their price objective on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, February 26th. Raymond James boosted their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Finally, Piper Sandler boosted their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $194.80.

Masimo Price Performance

NASDAQ MASI opened at $165.82 on Friday. The firm’s fifty day simple moving average is $174.99 and its two-hundred day simple moving average is $159.19. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo has a 12-month low of $101.61 and a 12-month high of $194.88. The firm has a market capitalization of $8.95 billion, a P/E ratio of 114.36 and a beta of 1.04.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Westfield Capital Management Co. LP raised its position in shares of Masimo by 23.2% in the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after acquiring an additional 262,370 shares during the period. National Bank of Canada FI raised its position in shares of Masimo by 195.6% in the third quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider’s stock worth $17,666,000 after acquiring an additional 87,675 shares during the period. Lecap Asset Management Ltd. acquired a new position in shares of Masimo in the fourth quarter worth about $1,607,000. Nisa Investment Advisors LLC raised its position in shares of Masimo by 16,740.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider’s stock worth $835,000 after acquiring an additional 5,022 shares during the period. Finally, Trust Point Inc. acquired a new position in shares of Masimo in the fourth quarter worth about $230,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Insider Activity at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now owns 16,581 shares of the company’s stock, valued at $2,754,601.53. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by insiders.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.